Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Orchid Pharma Appoints Key Leaders for Newly Established AMR Division

NextEdge Admin

04 Jul 2024

2 min 46 sec

Orchid Pharma has recently announced strategic appointments aimed at bolstering its leadership team in the fight against Antimicrobial Resistance (AMR). Dr. Prabhu Vinayagam has been appointed as Medical Advisor for Orchid AMS, a newly established division focused on antimicrobial stewardship. Dr. Prabhu brings a wealth of experience in healthcare leadership and antimicrobial stewardship, gained from key roles at Becton Dickinson, Joint Commission International – Asia Pacific, and as Group CEO at Mandalar Group of Hospitals in Myanmar. His expertise in reducing Hospital Acquired Infections (HAIs) and data-driven decision-making will be pivotal in Orchid Pharma's efforts to optimize antibiotic use and combat AMR.

Joining Dr. Prabhu is Amitabh Mazumdar, appointed as GM-Sales & Marketing for Orchid AMS. Mazumdar brings over three decades of experience in marketing, sales, and leadership within the pharmaceutical sector, with notable roles at GSK, Mylan (Viatris), and Merck Serono. His proficiency in launching and managing life cycles of pharmaceutical brands, along with his track record of successfully launching new business units, will play a crucial role in driving Orchid AMS's growth and success.

Rajnish Rohatgi, CEO of Orchid AMS, emphasized the strategic importance of these appointments, stating, "We are poised to significantly impact AMR management in India with a highly skilled and motivated team. We are delighted to welcome Dr. Prabhu and Amitabh, whose combined expertise will enable us to develop innovative solutions that comprehensively address AMR challenges faced by hospitals."

Orchid Pharma, renowned for its end-to-end capabilities in the pharmaceutical value chain, is primed to make substantial advancements in AMR management under its strengthened leadership team. These appointments underscore the company's commitment to combating AMR through strategic leadership and innovation in healthcare solutions.